HK1126483A1 - Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one - Google Patents

Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one

Info

Publication number: HK1126483A1
Authority: HK; Hong Kong
Prior art keywords: phthalazin; cyclopropanecarbonyl; piperazine; fluoro; carbonyl
Prior art date: 2006-10-17

Application number

HK09105082.9A

Other languages

English (en)

Inventor

Keith Allan Menear

Anthony Peter Ottridge

Derek John Londesbrough

Michael Raymond Hallett

Keith Raymond Mullholland

John David Pittam

David Dermot Patrick Laffan

Ian Woodward Ashworth

Martin Francis Jones

Janette Helen Cherryman

Original Assignee

Kudos Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-17

Filing date

2009-06-08

Publication date

2009-09-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38952365&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1126483(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-08 Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd

2009-09-04 Publication of HK1126483A1 publication Critical patent/HK1126483A1/xx

Links

FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK09105082.9A 2006-10-17 2009-06-08 Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one HK1126483A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82969406P	2006-10-17	2006-10-17
PCT/GB2007/003888 WO2008047082A2 (en)	2006-10-17	2007-10-15	Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one

Publications (1)

Publication Number	Publication Date
HK1126483A1 true HK1126483A1 (en)	2009-09-04

Family

ID=38952365

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK09105082.9A HK1126483A1 (en)	2006-10-17	2009-06-08	Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
HK15104656.0A HK1203959A1 (zh)	2006-10-17	2015-05-16	用於配製環丙甲酰基 -二氫- -氧代- -酞嗪基甲基 -氟苯甲酰呱嗪的方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK15104656.0A HK1203959A1 (zh)	2006-10-17	2015-05-16	用於配製環丙甲酰基 -二氫- -氧代- -酞嗪基甲基 -氟苯甲酰呱嗪的方法

Country Status (35)

Country	Link
US (2)	US7692006B2 (zh)
EP (3)	EP2374800A3 (zh)
JP (3)	JP5248513B2 (zh)
KR (2)	KR20140011425A (zh)
CN (3)	CN104649979B (zh)
AR (1)	AR063320A1 (zh)
AT (1)	ATE528296T1 (zh)
AU (1)	AU2007311766B2 (zh)
BR (1)	BRPI0717125B8 (zh)
CA (2)	CA2875147C (zh)
CL (1)	CL2007002967A1 (zh)
CO (1)	CO6210728A2 (zh)
CY (1)	CY1112345T1 (zh)
DK (1)	DK2064189T3 (zh)
ES (2)	ES2372630T3 (zh)
HK (2)	HK1126483A1 (zh)
HR (1)	HRP20120007T1 (zh)
IL (2)	IL197420A (zh)
ME (1)	ME01987B (zh)
MX (1)	MX2009004103A (zh)
MY (2)	MY147389A (zh)
NO (2)	NO341963B1 (zh)
NZ (1)	NZ575627A (zh)
PE (1)	PE20081175A1 (zh)
PL (1)	PL2064189T3 (zh)
PT (1)	PT2064189E (zh)
RS (1)	RS52112B (zh)
RU (1)	RU2465270C3 (zh)
SA (2)	SA07280551B1 (zh)
SG (2)	SG168523A1 (zh)
SI (1)	SI2064189T1 (zh)
TW (1)	TWI404716B (zh)
UA (1)	UA97494C2 (zh)
UY (1)	UY30639A1 (zh)
WO (1)	WO2008047082A2 (zh)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7151102B2 (en) *	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
GB0419072D0 (en) *	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
GB0428111D0 (en) *	2004-12-22	2005-01-26	Kudos Pharm Ltd	Pthalazinone derivatives
GB0521373D0 (en) *	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
WO2007144639A1 (en) *	2006-06-15	2007-12-21	Kudos Pharmaceuticals Limited	2 -oxybenzamide derivatives as parp inhibitors
JP2009539963A (ja) *	2006-06-15	2009-11-19	クドスファーマシューティカルズリミテッド	Ｐａｒｐ阻害剤
EP2041110A1 (en) *	2006-06-15	2009-04-01	Kudos Pharmaceuticals Limited	2 -oxyheteroarylamide derivatives as parp inhibitors
TWI404716B (zh) *	2006-10-17	2013-08-11	Kudos Pharm Ltd	酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US8466150B2 (en)	2006-12-28	2013-06-18	Abbott Laboratories	Inhibitors of poly(ADP-ribose)polymerase
RS53196B (en) *	2006-12-28	2014-06-30	Abbvie Inc.	INHIBITORI POLI (ADP-RIBOZA) POLIMERAZE
US20080280910A1 (en) *	2007-03-22	2008-11-13	Keith Allan Menear	Phthalazinone derivatives
TW200900396A (en) *	2007-04-10	2009-01-01	Kudos Pharm Ltd	Phthalazinone derivatives
BRPI0817537B1 (pt) *	2007-10-17	2022-04-05	Kudos Pharmaceuticals Limited	4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto
MX2011003740A (es)	2008-10-07	2011-05-02	Astrazeneca Uk Ltd	Formulacion farmaceutica - 514.
US20110015393A1 (en) *	2009-07-15	2011-01-20	Astrazeneca Ab	Phthalazinone compound
WO2012014221A1 (en)	2010-07-27	2012-02-02	Cadila Healthcare Limited	Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN102485721B (zh) *	2010-12-03	2015-12-09	曹亚	取代的2,3-二氮杂萘酮化合物及其用途
US10201521B2 (en)	2012-01-20	2019-02-12	Del Mar Pharmaceuticals (Bc) Ltd.	Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
MA38080A1 (fr)	2012-12-31	2018-02-28	Cadila Healthcare Ltd	Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1
JP2016519684A (ja)	2013-04-08	2016-07-07	デニスエムブラウン	準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
CA2946538A1 (en)	2014-04-04	2015-10-08	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
RU2736219C2 (ru)	2014-06-17	2020-11-12	Вертекс Фармасьютикалз Инкорпорейтед	Способ лечения рака с использованием комбинации ингибиторов снк1 и atr
CN105777651A (zh) *	2015-01-13	2016-07-20	江苏豪森药业集团有限公司	聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途
CN105985294B (zh) *	2015-02-11	2020-12-25	四川科伦药物研究院有限公司	一种奥拉帕尼的制备方法
WO2016165650A1 (zh) *	2015-04-17	2016-10-20	苏州晶云药物科技有限公司	奥拉帕尼与尿素的共晶及其制备方法
CN106146492A (zh) *	2015-04-17	2016-11-23	上海汇伦生命科技有限公司	杂环并咪唑类化合物、其药物组合物及其制备方法和用途
EP3298005B1 (en)	2015-05-21	2024-01-24	The Regents of The University of California	Anti-cancer compounds
CN112010809A (zh) *	2015-06-12	2020-12-01	苏州科睿思制药有限公司	奥拉帕尼的晶型i及其制备方法
CN105175370A (zh) *	2015-07-27	2015-12-23	安徽万邦医药科技有限公司	一种2-氟-5-[(3-氧代-1(3h)-异苯并呋喃亚基)甲基]苯腈的合成方法
KR20180054657A (ko)	2015-09-30	2018-05-24	버텍스 파마슈티칼스 인코포레이티드	Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법
CN105254572A (zh) *	2015-11-09	2016-01-20	北京科莱博医药开发有限责任公司	一种奥拉帕尼的晶型及其制备方法和应用
CN106699672B (zh) *	2015-11-16	2019-10-29	上海博邦医药科技有限公司	一种奥拉帕尼无定型物及其制备方法
ITUB20159206A1 (it) *	2015-12-22	2017-06-22	Olon Spa	Forme cristalline e amorfe di olaparib
US20170204067A1 (en) *	2016-01-14	2017-07-20	Scinopharm Taiwan, Ltd.	Crystalline forms of olaparib and manufacturing processes therefor
CZ201682A3 (cs)	2016-02-15	2017-08-23	Zentiva, K.S.	Solvatované krystalické formy olaparibu, jejich příprava a použití
CN105503739B (zh) *	2016-02-24	2018-09-11	合肥启旸生物科技有限公司	一种奥拉帕尼的制备方法
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
WO2017153958A1 (en) *	2016-03-11	2017-09-14	Lupin Limited	Novel polymorphic forms and amorphous form of olaparib
CN107304186B (zh) *	2016-04-25	2021-08-27	杭州容立医药科技有限公司	一种奥拉帕尼的精制方法
CN107304187B (zh) *	2016-04-25	2021-07-09	杭州容立医药科技有限公司	一种奥拉帕尼的重结晶方法
WO2017191562A1 (en) *	2016-05-04	2017-11-09	Alembic Pharmaceuticals Limited	Process for the preparation of olaparib and polymorphs thereof
KR102494294B1 (ko)	2016-06-24	2023-01-31	더 리전트 오브 더 유니버시티 오브 캘리포니아	Parp1, pap2 및/또는 튜블린의 저해제로서 암 치료에 유용한 프탈라진 유도체
EP3263529B1 (en)	2016-06-27	2019-11-06	Xylem Europe GmbH	Quartz sleeve support for an uv-lamp
CZ2016391A3 (cs)	2016-06-29	2018-01-10	Zentiva, K.S.	Farmaceutická formulace olaparibu
WO2018038680A1 (en)	2016-08-24	2018-03-01	Scinopharm Taiwan, Ltd.	Processes for preparing olaparib
WO2018122168A1 (en)	2016-12-29	2018-07-05	Bayer Pharma Aktiengesellschaft	Combinations of bub1 kinase and parp inhibitors
CN107098862A (zh) *	2017-06-05	2017-08-29	山东裕欣药业有限公司	一种奥拉帕尼二水合物及其制备方法
CN107325055A (zh) *	2017-08-14	2017-11-07	山东裕欣药业有限公司	一种奥拉帕尼化合物的合成方法
EP3674304B1 (en) *	2017-08-24	2022-04-13	Jiangsu Hengrui Medicine Co., Ltd.	Crystal form of parp-1 inhibitor and preparation method therefor
CN108101852A (zh) *	2017-12-27	2018-06-01	山东裕欣药业有限公司	一种奥拉帕尼的制备方法
WO2019133864A1 (en)	2017-12-29	2019-07-04	Accutar Biotechnology	DUAL INHIBITORS OF PARP1 and CDK
MA51524A (fr)	2018-01-05	2020-11-11	Cybrexa 1 Inc	Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
CA3031777A1 (en)	2018-01-31	2019-07-31	Apotex Inc.	Crystalline form of olaparib
CN110204530B (zh) *	2018-02-28	2020-05-08	新发药业有限公司	一种瓦他拉尼的制备方法
CN108558773A (zh) *	2018-05-17	2018-09-21	苏州莱克施德药业有限公司	一种奥拉帕尼药物中间体的制备方法
CN109535082A (zh) *	2018-12-24	2019-03-29	合肥创新医药技术有限公司	一种奥拉帕尼的制备方法
US10703728B1 (en)	2019-06-18	2020-07-07	Scinopharm Taiwan, Ltd.	Crystalline form of olaparib and a process for preparing the same
PE20220485A1 (es)	2019-07-10	2022-04-04	Cybrexa 3 Inc	Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos
CN114341162A (zh)	2019-07-10	2022-04-12	赛博克萨2公司	作为治疗剂的细胞毒素的肽缀合物
WO2021044437A1 (en) *	2019-09-04	2021-03-11	Cipla Limited	Olaparib co-crystals and process of preparation thereof
CN110563703B (zh) *	2019-09-18	2021-04-09	浙江省医学科学院	基于crbn配体诱导parp-1降解的化合物及制备方法和应用
CN116234803A (zh)	2019-12-23	2023-06-06	冰洲石生物科技公司	用于治疗癌症的***受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
CN111116514B (zh) *	2020-01-10	2024-03-19	广州科锐特生物科技有限公司	一种1-环丙甲酰基哌嗪盐酸盐的制备方法
CN115485271A (zh)	2020-04-28	2022-12-16	理森制药股份公司	用作聚(adp-核糖)聚合酶（parp）抑制剂的新型化合物
CN111995582B (zh) *	2020-07-09	2021-12-03	天津理工大学	一种奥拉帕尼与尿素的共晶及其制备方法
CN111689905B (zh) *	2020-07-22	2021-12-03	天津理工大学	一种奥拉帕尼与马来酸的共晶及其制备方法
JP7453475B2 (ja) *	2020-09-16	2024-03-19	ナフォーミックステクノロジーズリミテッド	オラパリブシュウ酸共結晶及びその医薬的使用
CN114249695A (zh) *	2020-09-21	2022-03-29	齐鲁制药有限公司	一种奥拉帕利的新晶型、制备方法及用途
WO2022090938A1 (en)	2020-10-31	2022-05-05	Rhizen Pharmaceuticals Ag	Phthalazinone derivatives useful as parp inhibitors
CN114539161B (zh) *	2020-11-11	2024-03-29	成都硕德药业有限公司	一种奥拉帕尼-尿素共晶及其制备方法
CN112661733A (zh) *	2020-12-23	2021-04-16	南京方生和医药科技有限公司	奥拉帕利杂质中间体、奥拉帕利杂质及其制备方法
CN112500379B (zh) *	2020-12-23	2024-01-23	南京方生和医药科技有限公司	一种奥拉帕利中间体及奥拉帕利的制备方法
JP2024503380A (ja)	2021-01-08	2024-01-25	サイブレクサ２，インコーポレイテッド	コンジュゲート連結部分を調製するための方法
WO2022155172A1 (en)	2021-01-13	2022-07-21	Cybrexa 3, Inc.	Peptide conjugates of therapeutics
AU2022255809A1 (en)	2021-04-08	2023-10-26	Incozen Therapeutics Pvt. Ltd.	Inhibitors of poly(adp-ribose) polymerase
CN113636979B (zh) *	2021-08-12	2023-06-13	天津理工大学	一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用
KR102645122B1 (ko)	2021-08-25	2024-03-07	주식회사 보령	올라파립의 제조방법
CN115448886A (zh) *	2022-10-11	2022-12-09	福建福瑞明德药业有限公司	一种奥拉帕利的制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3813384A (en)	1972-01-17	1974-05-28	Asta Werke Ag Chem Fab	Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US4665181A (en)	1984-05-17	1987-05-12	Pennwalt Corporation	Anti-inflammatory phthalazinones
US5041653A (en)	1985-05-03	1991-08-20	Sri International	Substituted benzamide radiosensitizers
US5215738A (en)	1985-05-03	1993-06-01	Sri International	Benzamide and nicotinamide radiosensitizers
US5032617A (en)	1985-05-03	1991-07-16	Sri International	Substituted benzamide radiosensitizers
EP0222191B1 (de)	1985-11-11	1991-01-30	ASTA Pharma AG	4-Benzyl-1-(2H)-phthalazinon-Derivate
ATE117553T1 (de)	1988-08-19	1995-02-15	Warner Lambert Co	Substituierte dihydroisochinolinone und verwandte verbindungen als verstärker der letalen effekte von bestrahlung und bestimmten chemotherapeutika; ausgewählte verbindungen, analoga und verfahren.
EP0389995B1 (en)	1989-03-28	1995-05-31	Nisshin Flour Milling Co., Ltd.	Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
GB9011833D0 (en)	1990-05-25	1990-07-18	Collins Mary K L	Inhibition of viral infection
MX9200299A (es)	1991-02-07	1992-12-01	Roussel Uclaf	Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en)	1991-02-07	1999-12-21	Hoechst Marion Roussel	Nitrogenous bicycles
EP0502575A1 (en)	1991-03-06	1992-09-09	Merck & Co. Inc.	Substituted 1-(2H)-isoquinolinones
CZ199593A3 (en)	1992-10-02	1994-04-13	Asta Medica Ag	Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
AU5455194A (en)	1992-11-02	1994-05-24	Merck & Co., Inc.	Substituted phthalazinones as nerotensin antagonists
EP0634404A1 (en)	1993-07-13	1995-01-18	Rhone Poulenc Agriculture Ltd.	Phtalazin derivatives and their use as pesticides
US5587384A (en)	1994-02-04	1996-12-24	The Johns Hopkins University	Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en)	1994-02-09	1997-07-15	Kos Pharmaceutical, Inc.	Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en)	1994-03-09	1994-04-20	Cancer Res Campaign Tech	Benzamide analogues
AU686004B2 (en)	1994-08-12	1998-01-29	Myriad Genetics, Inc.	In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
JP3399539B2 (ja)	1994-08-12	2003-04-21	ミリアド・ジェネティックス・インコーポレイテッド	乳癌および卵巣癌の素因の診断方法
US5589483A (en)	1994-12-21	1996-12-31	Geron Corporation	Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
WO1996031501A1 (en) *	1995-04-07	1996-10-10	Schering Corporation	Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
IL120264A0 (en)	1996-02-29	1997-06-10	Pfizer	Method of reducing tissue damage associated with non-cardiac ischemia
US5939557A (en)	1996-04-03	1999-08-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5883105A (en)	1996-04-03	1999-03-16	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5880140A (en)	1996-04-03	1999-03-09	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US6063930A (en)	1996-04-03	2000-05-16	Merck & Co., Inc.	Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5874452A (en)	1996-04-03	1999-02-23	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
AU727939B2 (en) *	1996-04-03	2001-01-04	Merck & Co., Inc.	A method of treating cancer
US5854265A (en)	1996-04-03	1998-12-29	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5859035A (en)	1996-04-03	1999-01-12	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en)	1996-04-03	1999-02-16	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
US6080870A (en)	1996-04-03	2000-06-27	Merck & Co., Inc.	Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
EP0952842A2 (en) *	1996-04-18	1999-11-03	Merck & Co., Inc.	A method of treating cancer
US5880128A (en)	1996-05-08	1999-03-09	Schering Corporation	Carbonyl piperazinyl and piperidinyl compounds
AU3215197A (en) *	1996-05-30	1998-01-05	Merck & Co., Inc.	A method of treating cancer
US5854264A (en)	1996-07-24	1998-12-29	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5888529A (en)	1997-03-28	1999-03-30	The Regents Of The University Of California	Ileus treatment method
US6060038A (en)	1997-05-15	2000-05-09	Merck & Co., Inc.	Radiolabeled farnesyl-protein transferase inhibitors
AU8784698A (en)	1997-08-15	1999-03-08	Johns Hopkins University, The	Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6635642B1 (en)	1997-09-03	2003-10-21	Guilford Pharmaceuticals Inc.	PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en)	1997-09-03	2001-03-06	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020022636A1 (en)	1997-09-03	2002-02-21	Jia-He Li	Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6426415B1 (en)	1997-09-03	2002-07-30	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en)	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6291425B1 (en)	1999-09-01	2001-09-18	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO1999025340A1 (en)	1997-11-14	1999-05-27	Eli Lilly And Company	Treatment for alzheimer's disease
JP2002505288A (ja)	1998-03-02	2002-02-19	コセンシス，インコーポレイテッド	置換キナゾリンおよびアナログならびにそれらの使用
US6951862B2 (en) *	1998-06-30	2005-10-04	Neuromed Technologies, Inc.	Calcium channel blockers comprising two benzhydril moieties
US7186726B2 (en) *	1998-06-30	2007-03-06	Neuromed Pharmaceuticals Ltd.	Preferentially substituted calcium channel blockers
US6387897B1 (en)	1998-06-30	2002-05-14	Neuromed Technologies, Inc.	Preferentially substituted calcium channel blockers
US20060084660A1 (en) *	1998-06-30	2006-04-20	Neuromed Technologies Inc.	Calcium channel blockers comprising two benzhydril moieties
US6492375B2 (en)	1998-06-30	2002-12-10	Neuromed Technologies, Inc.	Partially saturated calcium channel blockers
US20040266784A1 (en) *	1998-06-30	2004-12-30	Snutch Terrance P.	Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6943168B2 (en)	1998-06-30	2005-09-13	Neuromed Technologies Inc.	Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20040259866A1 (en) *	1998-06-30	2004-12-23	Snutch Terrance P.	Calcium channel blockers comprising two benzhydril moieties
US6310059B1 (en)	1998-06-30	2001-10-30	Neuromed Technologies, Inc.	Fused ring calcium channel blockers
US6011035A (en)	1998-06-30	2000-01-04	Neuromed Technologies Inc.	Calcium channel blockers
EP1148053A4 (en)	1999-01-26	2002-03-06	Ono Pharmaceutical Co	2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS
DE19921567A1 (de)	1999-05-11	2000-11-16	Basf Ag	Verwendung von Phthalazine-Derivaten
US6465467B1 (en)	1999-05-21	2002-10-15	Biovitrum Ab	Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
KR100634249B1 (ko)	1999-08-11	2006-10-17	브리스톨-마이어스스퀴브컴파니	파클리탁셀 ｃ-4 메틸 카르보네이트 동족체의 제조 방법
US6465448B1 (en)	1999-08-13	2002-10-15	Case Western Reserve University	Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es)	1999-08-31	2002-03-25	Agouron Pharma	Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en)	1999-09-17	2001-04-24	Yamanouchi Pharmaceutical Co., Ltd.	Benzimidazole derivatives
BR0007174A (pt)	1999-09-28	2001-09-04	Basf Ag	Composto, preparação farmacêutica e uso de compostos
US6552016B1 (en)	1999-10-14	2003-04-22	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6476048B1 (en)	1999-12-07	2002-11-05	Inotek Pharamaceuticals Corporation	Substituted phenanthridinones and methods of use thereof
DE19963607B4 (de)	1999-12-23	2005-12-15	Schering Ag	Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
AU2001240542A1 (en)	2000-02-01	2001-08-14	Basf Aktiengesellschaft	Heterocyclic compounds and their use as parp inhibitors
WO2001079184A1 (fr)	2000-04-18	2001-10-25	Sumitomo Pharmaceuticals Company, Limited	Composes de piperazine substitues
US7122679B2 (en)	2000-05-09	2006-10-17	Cephalon, Inc.	Multicyclic compounds and the use thereof
DE10022925A1 (de)	2000-05-11	2001-11-15	Basf Ag	Substituierte Indole als PARP-Inhibitoren
US6723733B2 (en)	2000-05-19	2004-04-20	Guilford Pharmaceuticals, Inc.	Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
AU7549501A (en)	2000-06-16	2002-01-02	Biogen Inc	Angiogenesis-modulating compositions and uses
US7498304B2 (en) *	2000-06-16	2009-03-03	Curis, Inc.	Angiogenesis-modulating compositions and uses
BR0115062A (pt) *	2000-10-30	2004-02-17	Kudos Pharm Ltd	Derivados de ftalazinona
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
WO2002044157A2 (en)	2000-12-01	2002-06-06	Iconix Pharmaceuticals, Inc.	Parb inhibitors
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
JPWO2002068407A1 (ja)	2001-02-28	2004-06-24	山之内製薬株式会社	ベンゾイミダゾール化合物
JP2004528376A (ja)	2001-05-08	2004-09-16	クドスファーマシューティカルズリミテッド	Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
EP1396488A1 (en)	2001-05-23	2004-03-10	Mitsubishi Pharma Corporation	Fused heterocyclic compound and medicinal use thereof
US20030073692A1 (en) *	2001-08-07	2003-04-17	Pharmacia & Upjohn S.P.A.	Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US7402580B2 (en)	2002-02-19	2008-07-22	Ono Pharmaceutical Co., Ltd.	Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
US20030195192A1 (en)	2002-04-05	2003-10-16	Fortuna Haviv	Nicotinamides having antiangiogenic activity
US20040014744A1 (en)	2002-04-05	2004-01-22	Fortuna Haviv	Substituted pyridines having antiangiogenic activity
DE60335359D1 (de)	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
PL1633724T3 (pl) *	2003-03-12	2011-10-31	Kudos Pharm Ltd	Pochodne ftalazynonu
GB0305681D0 (en) *	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
DK2305221T3 (en)	2003-12-01	2015-08-24	Kudos Pharm Ltd	DNA damage repair inhibitors for the treatment of cancer
US20050277629A1 (en) *	2004-03-18	2005-12-15	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies (Lansbury)
US20050227999A1 (en) *	2004-04-09	2005-10-13	Neuromed Technologies Inc.	Diarylamine derivatives as calcium channel blockers
EP1760071A4 (en) *	2004-06-23	2008-03-05	Ono Pharmaceutical Co	COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
US7517870B2 (en) *	2004-12-03	2009-04-14	Fondazione Telethon	Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
DE102005011822A1 (de) *	2005-03-15	2006-09-21	Merck Patent Gmbh	Phthalazinone
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
TWI404716B (zh) *	2006-10-17	2013-08-11	Kudos Pharm Ltd	酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
RS53196B (en)	2006-12-28	2014-06-30	Abbvie Inc.	INHIBITORI POLI (ADP-RIBOZA) POLIMERAZE
TW200900396A (en)	2007-04-10	2009-01-01	Kudos Pharm Ltd	Phthalazinone derivatives
BRPI0817537B1 (pt) *	2007-10-17	2022-04-05	Kudos Pharmaceuticals Limited	4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto

2007
- 2007-10-12 TW TW096138353A patent/TWI404716B/zh active
- 2007-10-12 UY UY30639A patent/UY30639A1/es not_active Application Discontinuation
- 2007-10-15 CA CA2875147A patent/CA2875147C/en active Active
- 2007-10-15 MX MX2009004103A patent/MX2009004103A/es active IP Right Grant
- 2007-10-15 EP EP11159495A patent/EP2374800A3/en not_active Withdrawn
- 2007-10-15 JP JP2009532883A patent/JP5248513B2/ja active Active
- 2007-10-15 KR KR1020147000557A patent/KR20140011425A/ko not_active Application Discontinuation
- 2007-10-15 DK DK07824140.3T patent/DK2064189T3/da active
- 2007-10-15 CA CA2664275A patent/CA2664275C/en active Active
- 2007-10-15 MY MYPI20091536A patent/MY147389A/en unknown
- 2007-10-15 SG SG201009564-4A patent/SG168523A1/en unknown
- 2007-10-15 KR KR20097007840A patent/KR101494910B1/ko active Protection Beyond IP Right Term
- 2007-10-15 MY MYPI2013000334A patent/MY162829A/en unknown
- 2007-10-15 SG SG10201408404XA patent/SG10201408404XA/en unknown
- 2007-10-15 EP EP14181346.9A patent/EP2824098B1/en active Active
- 2007-10-15 ES ES07824140T patent/ES2372630T3/es active Active
- 2007-10-15 CN CN201510002348.9A patent/CN104649979B/zh active Active
- 2007-10-15 WO PCT/GB2007/003888 patent/WO2008047082A2/en active Application Filing
- 2007-10-15 AU AU2007311766A patent/AU2007311766B2/en active Active
- 2007-10-15 PT PT07824140T patent/PT2064189E/pt unknown
- 2007-10-15 UA UAA200904210A patent/UA97494C2/ru unknown
- 2007-10-15 CN CN2007800388551A patent/CN101528714B/zh active Active
- 2007-10-15 RU RU2009109068A patent/RU2465270C3/ru active Protection Beyond IP Right Term
- 2007-10-15 PL PL07824140T patent/PL2064189T3/pl unknown
- 2007-10-15 BR BRPI0717125A patent/BRPI0717125B8/pt active IP Right Grant
- 2007-10-15 EP EP07824140A patent/EP2064189B1/en active Active
- 2007-10-15 CN CN201210060660XA patent/CN102627611A/zh active Pending
- 2007-10-15 ME MEP-2012-3A patent/ME01987B/me unknown
- 2007-10-15 NZ NZ575627A patent/NZ575627A/en unknown
- 2007-10-15 ES ES14181346.9T patent/ES2587129T3/es active Active
- 2007-10-15 SI SI200730792T patent/SI2064189T1/sl unknown
- 2007-10-15 RS RS20120003A patent/RS52112B/en unknown
- 2007-10-15 AT AT07824140T patent/ATE528296T1/de active
- 2007-10-16 AR ARP070104583A patent/AR063320A1/es not_active Application Discontinuation
- 2007-10-16 CL CL200702967A patent/CL2007002967A1/es unknown
- 2007-10-16 PE PE2007001394A patent/PE20081175A1/es active IP Right Grant
- 2007-10-17 US US11/873,671 patent/US7692006B2/en active Active
- 2007-10-20 SA SA07280551A patent/SA07280551B1/ar unknown
2009
- 2009-03-05 IL IL197420A patent/IL197420A/en active IP Right Grant
- 2009-05-12 CO CO09048110A patent/CO6210728A2/es not_active Application Discontinuation
- 2009-05-13 NO NO20091882A patent/NO341963B1/no unknown
- 2009-06-08 HK HK09105082.9A patent/HK1126483A1/xx unknown
- 2009-07-10 US US12/500,900 patent/US8247416B2/en active Active
2010
- 2010-08-23 SA SA110310666A patent/SA110310666B1/ar unknown
2011
- 2011-11-30 IL IL216705A patent/IL216705A/en active IP Right Grant
- 2011-12-29 CY CY20111101288T patent/CY1112345T1/el unknown
2012
- 2012-01-03 HR HR20120007T patent/HRP20120007T1/hr unknown
2013
- 2013-02-13 JP JP2013025205A patent/JP5607773B2/ja active Active
2014
- 2014-08-28 JP JP2014173377A patent/JP5719471B2/ja active Active
2015
- 2015-05-16 HK HK15104656.0A patent/HK1203959A1/zh unknown
2017
- 2017-11-09 NO NO20171775A patent/NO343063B1/no unknown

Also Published As

Publication number	Publication date
AU2007311766B2 (en)	2013-02-21
EP2064189A2 (en)	2009-06-03
NO343063B1 (no)	2018-10-22
US7692006B2 (en)	2010-04-06
NO20091882L (no)	2009-05-13
CO6210728A2 (es)	2010-10-20
MY147389A (en)	2012-11-30
IL216705A0 (en)	2012-01-31
PL2064189T3 (pl)	2012-03-30
DK2064189T3 (da)	2012-01-02
US20080146575A1 (en)	2008-06-19
CA2875147A1 (en)	2008-04-24
CN101528714B (zh)	2012-06-06
MX2009004103A (es)	2009-05-05
EP2824098B1 (en)	2016-06-22
IL197420A (en)	2015-07-30
CN104649979A (zh)	2015-05-27
JP2015013879A (ja)	2015-01-22
BRPI0717125B1 (pt)	2022-02-08
US8247416B2 (en)	2012-08-21
SA110310666B1 (ar)	2013-10-09
JP2010506894A (ja)	2010-03-04
TWI404716B (zh)	2013-08-11
WO2008047082A3 (en)	2008-09-25
JP2013136607A (ja)	2013-07-11
IL216705A (en)	2014-02-27
CY1112345T1 (el)	2015-12-09
AU2007311766A1 (en)	2008-04-24
UY30639A1 (es)	2008-05-31
US20090270617A1 (en)	2009-10-29
KR20140011425A (ko)	2014-01-28
JP5719471B2 (ja)	2015-05-20
NO341963B1 (no)	2018-03-05
SI2064189T1 (sl)	2012-01-31
ATE528296T1 (de)	2011-10-15
SG168523A1 (en)	2011-02-28
SA07280551B1 (ar)	2011-05-04
CA2664275A1 (en)	2008-04-24
NZ575627A (en)	2011-09-30
EP2824098A1 (en)	2015-01-14
ME01987B (me)	2012-08-31
TW200825066A (en)	2008-06-16
WO2008047082A2 (en)	2008-04-24
KR20090085033A (ko)	2009-08-06
CN104649979B (zh)	2017-04-12
CL2007002967A1 (es)	2008-04-18
BRPI0717125A2 (pt)	2013-12-17
NO20171775A1 (no)	2009-05-13
EP2374800A3 (en)	2012-02-29
JP5248513B2 (ja)	2013-07-31
CA2875147C (en)	2016-09-06
RS52112B (en)	2012-08-31
HRP20120007T1 (hr)	2012-01-31
CN102627611A (zh)	2012-08-08
RU2465270C3 (ru)	2017-03-28
AR063320A1 (es)	2009-01-21
BRPI0717125B8 (pt)	2023-01-10
PT2064189E (pt)	2012-01-05
ES2587129T3 (es)	2016-10-20
KR101494910B1 (ko)	2015-02-23
JP5607773B2 (ja)	2014-10-15
PE20081175A1 (es)	2008-11-06
SG10201408404XA (en)	2015-01-29
EP2374800A2 (en)	2011-10-12
ES2372630T3 (es)	2012-01-24
CA2664275C (en)	2015-03-17
HK1203959A1 (zh)	2015-11-06
UA97494C2 (en)	2012-02-27
EP2064189B1 (en)	2011-10-12
IL197420A0 (en)	2009-12-24
RU2465270C2 (ru)	2012-10-27
MY162829A (en)	2017-07-31
RU2009109068A (ru)	2010-11-27
CN101528714A (zh)	2009-09-09

Publication	Publication Date	Title
HK1126483A1 (en)	2009-09-04	Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
HK1142065A1 (zh)	2010-11-26	-環丙烷羰基-哌嗪- -羰基 -氟-苄基 -酞嗪- -酮
IL204991A0 (en)	2010-11-30	Polymorphic form of rotigotine
EP2057282A4 (en)	2010-10-27	MAPPING GENOMIC INTERACTIONS
PT2102192E (pt)	2013-01-23	Formas de estado sólido de ilaprazole racémico
GB0605553D0 (en)	2006-04-26	Casting composition
IL195158A0 (en)	2009-08-03	Novel heterocyclic compounds
ZA200808750B (en)	2009-12-30	Co-granulates of bleach activator-peroxide compounds
HK1189591A1 (zh)	2014-06-13	π- π- -羥基苯氧基氮雜環丁烷- -基 -甲基- -二苯基己酰胺的鹽酸鹽
GB0705854D0 (en)	2007-05-02	Methods of construction
ZA200902467B (en)	2010-03-31	Stabilized prostaglandin E composition
GB0624578D0 (en)	2007-01-17	Novel Composition
GB0621329D0 (en)	2006-12-06	Novel composition
HK1123525A1 (en)	2009-06-19	Control method of die-casting machine
GB2442073B (en)	2011-06-08	Concrete compositions
EP2340037A4 (en)	2012-05-09	METHOD OF ESTIMATING THE TGF-BETA LEVEL IN A COMPOSITION
EP2299981A4 (en)	2011-06-08	SUBLINGUAL COMPOSITIONS WITH (2S) - (4E) -N-METHYL-5- (3- (5-ISOPROPOXYPYRIDINE) YL) -4-PENTEN-2-AMINE
PL2083117T3 (pl)	2013-08-30	Kompozycja krzemionki
TWM298600U (en)	2006-10-01	Improved structure of clothespin set
ZA200903491B (en)	2010-07-28	Solid state forms of racemic ilaprazole
PL116895U1 (pl)	2009-01-19	Oprawa górna żaluzji
TWM311768U (en)	2007-05-11	Improved structure of A-ladder
GB0803829D0 (en)	2008-04-09	Flushing composition
ZA200809385B (en)	2009-10-28	Novel heterocyclic compounds
ITVI20060182A1 (it)	2007-12-15	Intonacatrice perfezionata